Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 27, 2017

View Archived Issues

Medivir reports promising topline data on MIV-711 in knee osteoarthritis

New Chiesi inhaled corticosteroid displays potency in airway inflammation models

Atopic asthma model devised in Sprague-Dawley rats using S. aureus enterotoxin B

ALM-201 is safe in phase I trial in patients with advanced solid tumors

Catalyst Biosciences' CB-2679d awarded FDA orphan drug status for hemophilia B

Fibrocell Sciences reports interim results of phase I/II study of FCX-007

Sputum PZP found to be a possible biomarker of bronchiectasis severity

Manageable safety seen with SL-801 in phase I trial

Pluristem planning phase III study of PLX-PAD cells for muscle recovery after arthroplasty

Genocea Biosciences to focus on neoantigen cancer vaccines

Asterias Biotherapeutics cleared to conduct clinical trials of allogenic cancer immunotherapy

vTv Therapeutics patents compounds for treating Alzheimer's disease

Poseida Therapeutics begins enrollment in phase I study of CAR T-cell therapy for multiple myeloma

Bayer Pharma identifies novel PGF receptor antagonists

Merck & Co. presents muscarinic M1 receptor modulators

Muscarinic M1 receptor PAMs described in Takeda patent

Novel tyrosine kinase inhibitors presented by NIBS

FDA accepts IND for Ocugen's OCU-310, proof-of-concept study begins

Acer Therapeutics reports results from pivotal study of Edsivo in vascular Ehlers-Danlos syndrome

EMA grants orphan drug designation to EDIT-101 for LCA10

Japanese approval for Cedarcure SLIT for Japanese cedar allergy

Phase I results for MOR-106 in patients with atopic dermatitis

Phase III study of intepirdine in Alzheimer's diseases misses co-primary efficacy endpoints

Herantis initiates first-in-human study of CDNF in Parkinson's disease

ImaginAb collaborates with Boehringer Ingelheim on CD8 T-cell imaging technology

Pfizer obtains approval for Ibrance in Japan

Topline results reported from Japanese phase II study of vadadustat in NDD-CKD

New mutation in SYNGAP1 gene tied to Ohtahara syndrome

Mateon terminates FOCUS study of CA4P for ovarian cancer

Darzalex approved in Japan for relapsed or refractory multiple myeloma

Maviret approved in Japan

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 24, 2024.
Enhanced Cognition: Lewy body dementia phase II pumps stock
BioWorld
Investors will get more details during the International Lewy Body Dementia Conference in Amsterdam late next month, but Wall Street is already buzzing about...
Experimental mRNA gene therapy suppresses preeclampsia in mice
BioWorld MedTech
A gene therapy based on an enhanced lipid nanoparticle (LNP) loaded with vascular endothelial growth factor (VEGF) mRNA could be developed for the treatment of...
Drug duo to Repare lack in gyno cancers? Phase I shows promise
BioWorld
Wall Street wasn’t jumping up and down about Repare Therapeutics Inc.’s early data in gynecological cancers, though the findings look positive and the company has...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.